Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | NMT1 | P30419 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 5/20 | 0.39 |
| ▸ | PROKR1 | Q8TCW9 | 5/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14759214 | 0.98 | KDM4E (0.51) | KDM4EPOLBAPEX1TDP1ALDH1A1 | |
| SCHEMBL2650212 | 0.79 | L3MBTL1 (0.46) | KDM4EPOLBAPEX1TDP1ALDH1A1 | |
| SCHEMBL347771 | 0.78 | TSHR (0.44) | ALDH1A1NPSR1TSHRGAAMAPT | |
| SCHEMBL4895697 | 0.78 | TSHR (0.44) | ALDH1A1NPSR1TSHRGAAMAPT | |
| SCHEMBL3376273 | 0.78 | TSHR (0.44) | KDM4EALDH1A1NPSR1TSHRGAA | |
| Hydrochloric Acid SCHEMBL27293487 | 0.78 | L3MBTL1 (0.45) | KDM4EPOLBAPEX1TDP1ALDH1A1 | |
| Fluoride SCHEMBL27733765 | 0.78 | L3MBTL1 (0.45) | KDM4EPOLBAPEX1TDP1ALDH1A1 | |
| SCHEMBL14468543 | 0.77 | ALDH1A1 (0.48) | KDM4EALDH1A1NPSR1TSHRGAA | |
| SCHEMBL13726542 | 0.75 | TSHR (0.42) | ALDH1A1NPSR1TSHRGAAMAPT | |
| SCHEMBL14149159 | 0.75 | TSHR (0.53) | KDM4EALDH1A1NPSR1TSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2462117-B1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V (DE) | 2017-06-28 | — | — | EP | claimed |
| CN-102993195-B | Substitutional-2-(chroman-6-oxyl) thiazole and application thereof as medicine | 赛诺菲 | 2017-05-17 | — | — | CN | claimed |
| US-9169241-B2 | Quinolinyloxyphenylsulfonamides | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2015-10-27 | — | — | US | claimed |
| US-8912224-B2 | Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals | SANOFI (FR) | 2014-12-16 | — | — | US | claimed |
| US-20140336191-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2014-11-13 | — | — | US | claimed |
| EP-2567958-B1 | Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals | SANOFI SA (FR) | 2014-10-29 | — | — | EP | claimed |
| US-20140243292-A1 | SUBSITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-08-28 | — | — | US | claimed |
| US-20130065859-A1 | SUBSTITUTED 2-(CHROMAN-6-YLOXY)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-03-14 | — | — | US | claimed |
| EP-2567958-A1 | Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals | SANOFI (FR) | 2013-03-13 | — | — | EP | claimed |
| US-20120277231-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2012-11-01 | — | — | US | claimed |
| US-20090209528-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-08-20 | — | — | US | claimed |
| US-20090131433-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2009-05-21 | — | — | US | claimed |
| CN-101410116-A | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-15 | — | — | CN | claimed |
| EP-1993554-A2 | UROTENSIN II RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-11-26 | — | — | EP | claimed |
| EP-1902025-A1 | KINASE INHIBITORS | Allergan, Inc. (US) | 2008-03-26 | — | — | EP | claimed |
| US-20070191391-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | claimed |
| WO-2007081995-A2 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-19 | — | — | WO | claimed |
| US-20070066587-A1 | Substituted azetidine compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2007-03-22 | — | — | US | claimed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | claimed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131433-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | HRH3, HRH4, HRH2 | KDM4E 3381/4885POLB 1820/4885APEX1 4755/4885 |
| US-20140336191-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | TP53, AQP1, KRAS | KDM4E 3979/4885POLB 459/4885APEX1 2924/4885 |
| US-20140243292-A1 | SUBSITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | RYR2, CACNA1E, SLC8B1 | KDM4E 3167/4885POLB 4869/4885APEX1 4548/4885 |
| US-20120277231-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | TP53, AQP1, KRAS | KDM4E 3979/4885POLB 459/4885APEX1 2924/4885 |
| US-20090209528-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND, THEIR PREPARATION AND USE IN MEDICAMENTS | HTR6, HTR5A, HTR7 | KDM4E 3367/4885POLB 3424/4885APEX1 4041/4885 |
| US-20130065859-A1 | SUBSTITUTED 2-(CHROMAN-6-YLOXY)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS | RYR2, SLC8B1, RYR1 | KDM4E 3199/4885POLB 4876/4885APEX1 4553/4885 |
| US-20070191391-A1 | Urotensin II receptor antagonists | UTS2R, PLAUR, BDKRB2 | KDM4E 4555/4885POLB 3854/4885APEX1 3192/4885 |
| US-20070066587-A1 | Substituted azetidine compounds, their preparation and use as medicaments | AZI2, NISCH, QDPR | KDM4E 1156/4885POLB 3957/4885APEX1 3075/4885 |
| US-20070032478-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | KDM4E 1393/4885POLB 1863/4885APEX1 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.